WST PEER ANALYSIS

West Pharmaceutical Services Inc — metric-by-metric comparison with peers and the industry median

WSTWest Pharmaceutical Services Inc

🇺🇸 USA · US · Healthcare · Medical Instruments & Supplies

Value itDuel

Overall Profile & Returns

· Medical Instruments & Supplies

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
WSTIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
WST+65.9%RMD-20.8%FPH-2.4%EL-25.2%ANN+6.2%
Year-to-Date (YTD)
WST+33.2%RMD-14.7%FPH+0.3%EL-34.7%ANN-6.2%

Key Metric Comparison

P/E

Lower is better
WST48.79RMD20.35FPH41.27EL34.91ANN24.16Median 34.91

ROE

Higher is better
WST19.1%RMD25.2%FPH23.3%EL5.8%ANN7.2%Median 2.3%

Net Margin

Higher is better
WST16.9%RMD27.4%FPH20.0%EL8.1%ANN6.7%Median 3.9%

Revenue Growth

Higher is better
WST11.2%RMD10.5%FPH4.8%EL7.5%ANN11.4%Median 6.4%

All Metrics

Valuation
MetricWSTRMDFPHELANNInd. Median
P/E48.7920.3541.2734.9124.1634.91
P/B8.854.739.082.081.662.95
EV/EBITDA31.1513.8323.2914.0112.5214.72
P/S8.225.568.272.841.582.79
Financial Health
MetricWSTRMDFPHELANNInd. Median
Current Ratio2.713.012.310.992.362.40
Debt/Equity10.6%13.0%6.9%37.0%46.2%34.8%
NetDebt/EBITDA-0.24-0.38-0.391.662.101.44
Profitability
MetricWSTRMDFPHELANNInd. Median
Net Margin16.9%27.4%20.0%8.1%6.7%3.9%
ROE19.1%25.2%23.3%5.8%7.2%2.3%
ROA14.0%18.6%17.3%3.6%4.2%1.5%
EBITDA Margin26.2%39.1%34.9%23.0%15.2%13.8%
Growth + Dividend
MetricWSTRMDFPHELANNInd. Median
Rev. Growth11.2%10.5%4.8%7.5%11.4%6.4%
NI Growth16.2%15.9%-11.6%-1.8%23.8%14.0%
Div. Yield0.2%8.0%1.6%2.3%1.7%1.7%
Payout11.4%22.4%53.9%0.0%53.2%22.4%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on WST

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.